 |
|
|
July 2008 Issue |
Volume 13, Number 7 |
|
|
|
Lead Stories for this Issue |
|
|
|
For NME Approvals, 2008 Looks A Lot Like 2007 At Mid-Year; Will Changes At FDA Turn The Tide?
The Score At The Half
The Second Half Lineup
Go to This Issue >>
|
|
|
|
|
June 2008 Issue |
Volume 13, Number 6 |
|
|
|
Lead Stories for this Issue |
|
|
|
Pfizer Trying A Novel Oncology Business Unit To Maximize Its Novel Pipeline
From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
Go to This Issue >>
|
|
|
|
|
May 2008 Issue |
Volume 13, Number 5 |
|
|
|
Lead Stories for this Issue |
|
|
|
Roche Exorcizes Torcetrapib’s Ghost: CETP Candidate Starts Phase III
Genzyme Sets Sights On 13 Drug Approvals By 2012; Only 2 Are NMEs
Antimicrobial Resistance Rallies Calls For Active FDA, R&D Incentives
Go to This Issue >>
|
|
|
|
|
 |
 |
 |
|
|
|
A D V E R T I S E M E N T
|
|
|
 |
|
 |
|
|
|
